METHODS: We retrospectively analyzed 147 HER2 + BC patients treated with NAC, including 85 from the Yale Response dataset (training cohort) and 62 from the IMPRESS HER2+ dataset (external validation cohort). Here, ERBB2 is linked to breast cancer.